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1. INTRODUCTION {#cas14026-sec-0001}
===============

Renal cell carcinoma (RCC), the most common kidney cancer, originates from renal tubular epithelium and includes various subtypes.[1](#cas14026-bib-0001){ref-type="ref"} One subtype, TFE3 Xp11 translocation RCC (tRCC),[2](#cas14026-bib-0002){ref-type="ref"} initially described in 1996,[3](#cas14026-bib-0003){ref-type="ref"}, [4](#cas14026-bib-0004){ref-type="ref"} was included in 2004 in the World Health Organization classification of renal cell tumors.[1](#cas14026-bib-0001){ref-type="ref"}, [5](#cas14026-bib-0005){ref-type="ref"} Translocation RCC, once considered rare, is now known to be the cause of RCC in 42% of RCCs seen in children and young adults.[6](#cas14026-bib-0006){ref-type="ref"} Xp11 tRCC is characterized by a chromosomal translocation with a breakpoint at Xp11.2 in the *TFE3* gene,[2](#cas14026-bib-0002){ref-type="ref"}, [7](#cas14026-bib-0007){ref-type="ref"} which encodes a member of the microphthalmia transcription factor (MiT) family.[8](#cas14026-bib-0008){ref-type="ref"}, [9](#cas14026-bib-0009){ref-type="ref"} Five *TFE3* gene fusions (*PRCC‐TFE3*,*ASPSCR1‐TFE3*,*SFPQ‐TFE3*,*NONO‐TFE3*, and *CLTC‐TFE3*) have been identified in patients with Xp11 tRCC,[2](#cas14026-bib-0002){ref-type="ref"}, [3](#cas14026-bib-0003){ref-type="ref"}, [7](#cas14026-bib-0007){ref-type="ref"}, [10](#cas14026-bib-0010){ref-type="ref"} and *ASPSCR1‐TFE3* is also known to cause alveolar soft part sarcoma (ASPS).[2](#cas14026-bib-0002){ref-type="ref"}, [7](#cas14026-bib-0007){ref-type="ref"} All of these fusion genes give rise to constitutively active, chimeric TFE3 proteins.[2](#cas14026-bib-0002){ref-type="ref"}, [7](#cas14026-bib-0007){ref-type="ref"} Clinically, Xp11 tRCC has the propensity to become an aggressive cancer and is often marked by recurrence and metastasis.[11](#cas14026-bib-0011){ref-type="ref"} However, RCCs, including Xp11 tRCC, do not generally show early clinical symptoms, and there are as yet no early diagnostic markers for RCC.

Liquid biopsy, defined as analysis of nucleic acids in body fluids, such as blood, urine, or saliva, is minimally invasive relative to conventional biopsy and is receiving attention as a potential cancer diagnostic to assess response to treatment and monitor recurrence.[12](#cas14026-bib-0012){ref-type="ref"}, [13](#cas14026-bib-0013){ref-type="ref"}, [14](#cas14026-bib-0014){ref-type="ref"} Numerous microRNAs (miRNAs) derived from tumor cells reportedly reside in body liquids,[14](#cas14026-bib-0014){ref-type="ref"}, [15](#cas14026-bib-0015){ref-type="ref"}, [16](#cas14026-bib-0016){ref-type="ref"} often interacting with proteins in microvesicles, such as exosomes, where they are resistant to ribonucleases and thus more stable.[14](#cas14026-bib-0014){ref-type="ref"}, [17](#cas14026-bib-0017){ref-type="ref"}, [18](#cas14026-bib-0018){ref-type="ref"} MicroRNA expression profiles reportedly differ between cancer types,[19](#cas14026-bib-0019){ref-type="ref"} and recent studies showed that miRNAs in body liquids could serve as biomarkers to diagnose lung, breast, colorectal, and renal cancers.[14](#cas14026-bib-0014){ref-type="ref"}, [20](#cas14026-bib-0020){ref-type="ref"}, [21](#cas14026-bib-0021){ref-type="ref"}, [22](#cas14026-bib-0022){ref-type="ref"}, [23](#cas14026-bib-0023){ref-type="ref"}

One hurdle to developing diagnostic biomarkers for rare cancers, including Xp11 tRCC, is difficulty in obtaining sufficient clinical samples. Here, we overcome this hurdle by generating transgenic (Tg) mice overexpressing a human *PRCC‐TFE3* fusion gene in renal tubular epithelial cells as an Xp11 tRCC mouse model. We observed increased microRNA (miR)‐204‐5p levels in urinary exosomes from renal *PRCC‐TFE3* Tg mice compared to control mice. Moreover, miR‐204‐5p expression levels were significantly elevated in primary cancer cell lines established either from tumors from renal *PRCC‐TFE3* Tg mice or tumors from 2 independent human Xp11 tRCC patients, and these cancer cells secreted miR‐204‐5p‐containing exosomes. Interestingly, we also observed increased miR‐204‐5p levels in urinary exosomes from renal *PRCC‐TFE3* Tg mice prior to tRCC development, suggesting that miR‐204‐5p increases as a consequence of constitutively active TFE3 chimeric proteins in renal tubular epithelial cells rather than as a consequence of tRCC development. We conclude that miR‐204‐5p in urinary exosomes could be a useful biomarker for early diagnosis of patients with Xp11 tRCC.

2. MATERIALS AND METHODS {#cas14026-sec-0002}
========================

2.1. Animal studies {#cas14026-sec-0003}
-------------------

The Institutional Animal Care and Use Committee of Kumamoto University (Kumamoto, Japan) approved all experiments in accordance with international and national guidelines. All animals were bred in a mouse house with automatically controlled lighting (12 hours on, 12 hours off), and maintained at a stable temperature of 23°C. Genetically engineered mice used in this study were Tg mice overexpressing *Cre* driven by the murine *Cadherin16* promoter (*Cdh16‐Cre*)[24](#cas14026-bib-0024){ref-type="ref"} on a C57BL/6N background. Procedures for urine collection, kidney echography, and measurement of blood urea nitrogen and creatinine concentrations in serum samples are provided in Data [S1](#cas14026-sup-0009){ref-type="supplementary-material"}.

2.2. Generation of *Rosa26* ^*PRCC‐TFE3/+*^ transgenic mice {#cas14026-sec-0004}
-----------------------------------------------------------

A donor vector used to generate *Rosa26* ^*PRCC‐TFE3/+*^ Tg mice was constructed using the pRosa26‐DEST vector (Addgene, Watertown, MA, USA), according to the manufacturer\'s instructions. For combinational use of the CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR associated proteins) system, a set of single guide RNA oligos (5′‐caccGACTGGAGTTGCAGATCACG‐3′ and 5′‐aaacCGTGATCTGCAACTCCAGTC‐3′) was cloned into *Bbs*I‐digested pX330 vector (Addgene). Cells (2 × 10^6^) from the C57BL/6‐derived ES line 6NK7[25](#cas14026-bib-0025){ref-type="ref"} were coelectroporated with 10 μg of a circular form of the donor vector harboring the human *PRCC‐TFE3* fusion gene plus 7.5 μg pX330 plasmid using Nucleofector (Lonza, Basel, Switzerland) and then plated on 10‐cm plates. G418 (160 μg/mL) selection was begun 24 hours later, and then 8 days later, 36 colonies were picked and stocked. Chimeric mice were produced by aggregation of ES cells with 8‐cell embryos of ICR mice (CLEA, Tokyo, Japan). Chimeric male founders were mated with C57BL/6NJcl females (CLEA) to generate F1 heterozygotes for the *Rosa26* ^*PRCC‐TFE3/+*^ line. Genotyping of tail DNA was carried out using the following the primers: Rosa26‐S (5′‐GTTTCCGACTTGAGTT‐3′) and Rosa26‐AS (5′‐AACCCCAGATGACTAC‐3′) to detect the WT allele; and mRosa26‐S (5′‐GGCGGACTGGCGGGACTA‐3′) and mRosa26‐AS (5′‐GGGACAGGATAAGTATGACATCATCAAGG‐3′) to detect the mutant allele.

2.3. Cell culture {#cas14026-sec-0005}
-----------------

The mouse renal tubular epithelial cell line M‐1 and the human renal tubular epithelial cell line HK‐2 were obtained from ATCC (Manassas, VA, USA). M‐1 cells, mouse tRCC cell lines, and human immortalized Xp11 tRCC cell lines (UOK120 and UOK124)[3](#cas14026-bib-0003){ref-type="ref"} were maintained in DMEM supplemented with 10% FCS. HK‐2 cells were maintained in DMEM/F‐12 medium supplemented with 10% FCS under 5% CO~2~ and 95% air.

Human embryonic HEK293 cells harboring a *PRCC‐TFE3* fusion gene (HEK293/PRCC‐TFE3) were maintained in DMEM containing 10% FCS, 150 μg/mL hygromycin, and 15 μg/mL blasticidin. To induce expression of the fusion gene, cells were treated with 100 ng/mL doxycycline for 48 hours.

For PRCC‐TFE3 knockdown, human Xp11 tRCC cells and HEK293/PRCC‐TFE3 cells were transfected with 1 of 2 *TFE3*‐specific siRNAs or with negative control siRNA. Details relevant to PRCC‐TFE3 knockdown are provided in Data [S1](#cas14026-sup-0009){ref-type="supplementary-material"}.

2.4. Immunocytochemistry {#cas14026-sec-0006}
------------------------

Immunocytochemical analysis of cultured cells was carried out with anti‐TFE3 Ab (Sigma‐Aldrich, St. Louis, MO, USA). Details relevant to immunocytochemistry are provided in Data [S1](#cas14026-sup-0009){ref-type="supplementary-material"}.

2.5. Histological analysis {#cas14026-sec-0007}
--------------------------

Histological analysis was undertaken as described.[26](#cas14026-bib-0026){ref-type="ref"} In brief, mouse kidney tissue samples were fixed in 4% paraformaldehyde overnight, embedded in paraffin, and cut in 4‐μm‐thick sections. Sections were then deparaffinized, stained with H&E, and analyzed using a BZ‐X710 microscope (Keyence, Osaka, Japan).

2.6. Immunohistochemistry {#cas14026-sec-0008}
-------------------------

For TFE3 immunohistochemistry, deparaffinized sections were pretreated with 3% H~2~O~2~ in TBS (pH 7.6) to inhibit endogenous peroxidases. Sections were then heated to 121°C for 15 minutes in Target Retrieval Solution (Dako Japan, Tokyo, Japan), blocked with 5% goat serum, and incubated with anti‐TFE3 Ab (Sigma‐Aldrich, 1:100) overnight at 4°C. After washing with TBS, sections were incubated with EnVision+System‐HRP Labelled Polymer Anti‐Rabbit (Dako Japan) as secondary Ab for 1 hour at room temperature. Sections were washed with TBS, and peroxidase activity was visualized by incubation with a 3,3‐diaminobenzidine solution followed by hematoxylin counterstaining. Images were analyzed using a BZ‐X710 microscope (Keyence).

2.7. Quantitative PCR array analysis of miRNAs {#cas14026-sec-0009}
----------------------------------------------

Quantitative PCR array analysis of miRNAs in urinary exosomes was carried out using miRCURY LNA miRNA Custom PCR Panels (Exiqon; Qiagen, Hilden, Germany). Detailed information about quantitative PCR (qPCR) array analysis is provided in Data [S1](#cas14026-sup-0009){ref-type="supplementary-material"}.

2.8. Exosome isolation {#cas14026-sec-0010}
----------------------

Mouse and human tRCC cell lines were maintained in DMEM containing 10% FCS and then changed to serum‐free medium for 48 hours. Medium was then collected, centrifuged at 10 000 *g* for 30 minutes at room temperature, and concentrated with a Vivaspin‐20 concentrator (Sartorius, Göttingen, Germany). These concentrated samples served as culture supernatants. Exosomes were isolated from supernatants using the MagCapture Esoxome Isolation Kit PS (FujiFilm Wako, Osaka, Japan).

Urinary exosomes were isolated from pooled urine samples (3 mL) from mice using the miRCURY Exosome Isolation Kit (Exiqon; Qiagen).

2.9. Quantitative real‐time PCR {#cas14026-sec-0011}
-------------------------------

For real‐time PCR analysis of *TRPM1* and *TRPM1* genes, PCR was carried out using TB Green Premix Ex Taq II (TaKaRa Bio, Shiga, Japan). Primer pairs are shown in Table [S1](#cas14026-sup-0006){ref-type="supplementary-material"}. Relative transcript abundance was normalized to that of *RPS18*. For real‐time PCR analysis of miRNAs, PCR was carried out using a miRCURY LNA SYBR Green PCR Kit (Exiqon; Qiagen) and miRCURY LNA Universal RT microRNA PCR Primers (Exiqon; Qiagen) (Table [S2](#cas14026-sup-0007){ref-type="supplementary-material"}). Relative transcript abundance was normalized to that of miR‐103‐3p. Detailed information relevant to quantitative real‐time PCR is provided in Data [S1](#cas14026-sup-0009){ref-type="supplementary-material"}.

2.10. Western blot analysis {#cas14026-sec-0012}
---------------------------

Protein extracts were subjected to SDS‐PAGE, and proteins were electrotransferred to PVDF membrane. Immunoblotting was undertaken with Abs against TFE3 (Sigma‐Aldrich), GAPDH (D16H11; Cell Signaling Technology, Danvers, MA, USA), histone H3 (D1H2; Cell Signaling Technology), and Hsc70 (B‐6; Santa Cruz Biotechnology, Dallas, TX, USA). Detailed information relevant to protein extraction from cultured cells is provided in Data [S1](#cas14026-sup-0009){ref-type="supplementary-material"}.

2.11. Statistics {#cas14026-sec-0013}
----------------

Statistical significance was assessed using Student\'s *t* test or the Mann‐Whitney *U* test. Mouse survival data were analyzed by the Kaplan‐Meier log‐rank test using JMP7 software (SAS Institute, Cary, NC, USA). Data are presented as means ± SEM, and a *P* value of \<.05 is defined as statistically significant.

3. RESULTS {#cas14026-sec-0014}
==========

3.1. Generation of Xp11 tRCC model mice {#cas14026-sec-0015}
---------------------------------------

To establish a tRCC model mouse, we first generated Tg mice conditionally overexpressing a human *PRCC‐TFE3* fusion gene in the *Rosa26* locus (*Rosa26* ^*PRCC‐TFE3/+*^ Tg mice) using homologous recombination (Figure [1](#cas14026-fig-0001){ref-type="fig"}A). To express the fusion gene in renal tubular epithelial cells, *Rosa26* ^*PRCC‐TFE3/PRCC‐TFE3*^ Tg mice were bred with *Cadherin16* (*Cdh16*)‐*Cre* Tg mice[24](#cas14026-bib-0024){ref-type="ref"} to establish Xp11 tRCC model (renal *PRCC‐TFE3* Tg mice) mice (Figure [1](#cas14026-fig-0001){ref-type="fig"}B). *Rosa26* ^*PRCC‐TFE3/+*^ Tg mice served as controls.

![Generation of an Xp11 translocation renal cell carcinoma mouse model. A,B, Schematic showing the WT *Rosa26* locus, the donor vector used to generate *Rosa26* ^*PRCC*^ ^*‐*^ ^*TFE*^ ^*3/+*^ transgenic (Tg) mice, and the mutant allele (*Rosa26* ^*PRCC*^ ^*‐*^ ^*TFE*^ ^*3/+*^) after CRISPR/Cas9‐mediated homologous recombination (A). Renal *PRCC‐TFE3* Tg (*Rosa26* ^*PRCC*^ ^*‐*^ ^*TFE*^ ^*3/+*^ and *Cadherin16* \[*Cdh16*\]*‐Cre*), and control (*Rosa26* ^*PRCC*^ ^*‐*^ ^*TFE*^ ^*3/+*^) mice were generated by breeding *Rosa26* ^*PRCC*^ ^*‐*^ ^*TFE*^ ^*3/*^ ^*PRCC*^ ^*‐*^ ^*TFE*^ ^*3*^ Tg with *Cdh16*‐*Cre* Tg mice (B). C, Representative echography recordings of right kidney of 30‐wk‐old control (Control), *Cdh16‐Cre*, and renal *PRCC‐TFE3* Tg (Tg) mice. D, Gross appearance of kidney of 40‐wk‐old control, *Cdh16‐Cre*, and renal *PRCC‐TFE3* Tg mice. E, Representative H&E‐stained images of longitudinal sections of kidney tissues of 40‐wk‐old control, *Cdh16‐Cre*, and renal *PRCC‐TFE3* Tg mice. Bottom panels are magnifications of corresponding squares at top. Scale bar, 1 mm (top), 100 μm (bottom). F, Immunohistochemical staining for TFE3 in kidney tissues of 40‐wk‐old control, *Cdh16‐Cre*, and renal *PRCC‐TFE3* Tg mice. Scale bar, 100 μm (top), 50 μm (bottom). G, Kaplan‐Meier survival curves of control (n = 10), *Cdh16‐Cre* (n = 9), and renal *PRCC‐TFE3* Tg (n = 10) mice. \*\**P *\<* *.001, log‐rank test](CAS-110-1897-g001){#cas14026-fig-0001}

To assess tRCC development in model mice, we undertook echography of the kidney of control and renal *PRCC‐TFE3* Tg mice every 10 weeks from 10 to 40 weeks of age. We observed no difference between control and Tg mice at either 10 or 20 weeks of age (Figure [S1](#cas14026-sup-0001){ref-type="supplementary-material"}). However, at 30 and 40 weeks, renal *PRCC‐TFE3* Tg mice showed renal swelling relative to control or *Cdh16‐Cre* mice (Figure [1](#cas14026-fig-0001){ref-type="fig"}C,D). Histological analysis of kidney tissues from 40‐week‐old mice also revealed the disappearance of the boundary of the renal cortex and medulla, as well as dilated renal tubules showing multilayered tubular epithelium, cyst formation, and tumor development with papillary structure in Tg but not control or *Cdh16‐Cre* mice (Figure [1](#cas14026-fig-0001){ref-type="fig"}E). Immunohistochemistry for TFE3 revealed no TFE3‐positive cells in kidney tissues of control or *Cdh16‐Cre* mice; however, renal tubular epithelial cells and tumor cells in kidney tissues of renal *PRCC‐TFE3* Tg mice showed markedly increased expression of PRCC‐TFE3 chimeric proteins localized in cell nuclei (Figure [1](#cas14026-fig-0001){ref-type="fig"}F). Moreover, survival of renal *PRCC‐TFE3* Tg mice was significantly shortened compared with that of control or *Cdh16‐Cre* mice (Figure [1](#cas14026-fig-0001){ref-type="fig"}G). The overall time course of these changes indicates that precancerous changes occurring in kidney tissue are detectable in renal *PRCC‐TFE3* Tg mice.

Although renal *PRCC‐TFE3* Tg mice showed shortened survival periods, they exhibited no signs of tumor metastasis. Moreover, we observed no significant difference in body weight between control and renal *PRCC‐TFE3* Tg mice at 20 weeks of age; in contrast, by 40 weeks, renal *PRCC‐TFE3* Tg mice showed significantly decreased body weight compared with control mice (Figure [S2A](#cas14026-sup-0002){ref-type="supplementary-material"}). In addition, at 40 weeks of age, levels of serum blood urea nitrogen and creatinine in renal *PRCC‐TFE3* Tg mice were significantly higher than those seen in control mice (Figure [S2B](#cas14026-sup-0002){ref-type="supplementary-material"}), suggestive of renal failure. Taken together, these results suggest that the cause of death of renal *PRCC‐TFE3* Tg mice was likely debilitation due to tumor development‐associated renal failure.

3.2. Elevated miR‐204‐5p and miR‐211‐5p levels in urinary exosomes are associated with Xp11 tRCC development {#cas14026-sec-0016}
------------------------------------------------------------------------------------------------------------

Several miRNAs are reportedly targets of TFE3 fusion proteins.[2](#cas14026-bib-0002){ref-type="ref"}, [27](#cas14026-bib-0027){ref-type="ref"}, [28](#cas14026-bib-0028){ref-type="ref"}, [29](#cas14026-bib-0029){ref-type="ref"} Given the nuclear accumulation of PRCC‐TFE3 fusion proteins seen in Tg mice (Figure [1](#cas14026-fig-0001){ref-type="fig"}E), we hypothesized that some miRNAs might be secreted into the urine. To examine this possibility, we carried out qPCR array analysis of miRNAs in urinary exosomes isolated from pooled urine of 30‐week‐old control or renal *PRCC‐TFE3* Tg mice (Figure [2](#cas14026-fig-0002){ref-type="fig"}A). Of 754 miRNAs examined, we excluded 739 from further analysis based on the following criteria: (a) a raw Cq value of samples from Tg mice of \>37, (b) a ratio of miRNA levels from Tg vs control mice of \<5.0, and (c) lack of conservation with human miRNAs. We then undertook qPCR analysis of the 15 remaining miRNAs at both 20 and 40 weeks of age in both Tg and control mice (Figure [2](#cas14026-fig-0002){ref-type="fig"}B). Levels of 13 of the 15 candidates did not differ significantly between control and Tg mice. Of the remaining 2 candidates, levels of miR‐204‐5p significantly increased in Tg mice relative to controls at both 20 and 40 weeks of age. A second candidate, miR‐211‐5p, was not detected in urinary exosomes of control mice at either 20 or 40 weeks, whereas Tg mice showed significant levels of miR‐211‐5p in urinary exosomes at both time points. Moreover, levels of both miR‐204‐5p and miR‐211‐5p in urinary exosomes were comparable in 20‐ and 40‐week‐old Tg mice, suggesting that changes in their expression are detectable prior to overt tRCC development.

![Analysis of microRNA (miRNA) levels in urinary exosomes of renal *PRCC‐TFE3* transgenic (Tg) mice. A, Overview of the quantitative PCT (qPCR) array analysis‐based screening of miRNAs in urinary exosomes of renal *PRCC‐TFE3* Tg mice to identify biomarker candidates. The qPCR array analysis was carried out using exosomal RNA isolated from pooled urine of 30‐wk‐old control and renal *PRCC‐TFE3* Tg mice. The number of candidates excluded based on indicated criteria is shown in parentheses. B, Relative expression levels of 15 candidate miRNAs in exosomes isolated from urine samples from 20‐ or 40‐wk‐old control (Control) and renal *PRCC‐TFE3* Tg (Tg) mice (n = 6). Data are means ± SEM. \*\**P *\<* *.01. N.D., not detected](CAS-110-1897-g002){#cas14026-fig-0002}

3.3. Exosomes containing miR204‐5p and miR‐211‐5p are secreted from cancer cells {#cas14026-sec-0017}
--------------------------------------------------------------------------------

We next asked whether miR‐204‐5p and miR‐211‐5p are secreted from cancer cells in kidneys of renal *PRCC‐TFE3* Tg mice. To do so, we independently established 2 cancer cell lines, tRCC1 and tRCC2, from tumor tissues from 2 Tg mice. Immunoblotting analysis using a TFE3 Ab revealed marked expression of the PRCC‐TFE3 fusion protein in both lines (Figures [3](#cas14026-fig-0003){ref-type="fig"}A and [S3A](#cas14026-sup-0003){ref-type="supplementary-material"}). We also detected endogenous TFE3 in the mouse renal tubular epithelial cell line M‐1, although its expression level was lower than that of PRCC‐TFE3 fusion proteins in tRCC1 and tRCC2 lines (Figures [3](#cas14026-fig-0003){ref-type="fig"}A and [S3A](#cas14026-sup-0003){ref-type="supplementary-material"}). Furthermore, we observed nuclear accumulation of PRCC‐TFE3 fusion proteins in tRCC1 and tRCC2 lines but did not observe nuclear endogenous TFE3 proteins in M‐1 cells (Figures [3](#cas14026-fig-0003){ref-type="fig"}B and [S3B](#cas14026-sup-0003){ref-type="supplementary-material"}).

![MicroRNA (miR)‐204‐5p and miR‐211‐5p are upregulated in a cancer cell line established from tumor tissues of renal *PRCC‐TFE3* transgenic (Tg) mice. A, Representative immunoblotting (IB) of endogenous TFE3 protein or PRCC‐TFE3 chimeric protein in the mouse renal tubular epithelial cell line M‐1 and the translocation renal cell carcinoma cell line tRCC1. Hsc70 served as a loading control. B, Immunofluorescent staining for TFE3 (red) in M‐1 and tRCC1 cells. Nuclei were counterstained with DAPI (blue). Scale bar, 100 μm. C,D, Relative miR‐204‐5p and miR‐211‐5p levels in total RNA isolated from M‐1 and tRCC1 cells (n = 4) (C) and exosomal RNA isolated from M‐1 and tRCC cell supernatants (n = 3) (D). E, Relative *Trpm3* and *Trpm1* expression in M‐1 and tRCC cells (n = 6). Data are means ± SEM. \*\**P *\<* *.01. N.D., not detected](CAS-110-1897-g003){#cas14026-fig-0003}

We next assessed miR‐204‐5p and miR‐211‐5p expression levels in tRCC1, tRCC2, and M‐1 lines (Figures [3](#cas14026-fig-0003){ref-type="fig"}C and [S3C](#cas14026-sup-0003){ref-type="supplementary-material"}). We did not detect miR‐204‐5p or miR‐211‐5p in M‐1 cells; however, tRCC1 and tRCC2 cells abundantly expressed both miRNAs. MicroRNA‐204‐5p levels in exosomes isolated from supernatants of cultured tRCC1 and tRCC2 cells were also elevated compared to levels seen in M‐1 cells (Figures [3](#cas14026-fig-0003){ref-type="fig"}D and [S3D](#cas14026-sup-0003){ref-type="supplementary-material"}). However, we did not detect miR‐211‐5p in exosomes from tRCC2 cell supernatants (Figure [S3D](#cas14026-sup-0003){ref-type="supplementary-material"}). Overall, these results suggest that exosomes containing miR‐204‐5p or miR‐211‐5p are secreted from some tRCC lines.

In humans and mice, miR‐211 and miR‐204 genes are contained in introns of transient receptor potential cation channel subfamily M member 1 (*TRPM1*) and *TRPM3* genes, respectively, suggesting that expression of both miRNAs and *TRPM1* or *TRPM3* is coregulated by PRCC‐TFE3 fusion proteins. To investigate this possibility, we monitored *Trpm1* and *Trpm3* expression in tRCC1, tRCC2, and M‐1 lines (Figures [3](#cas14026-fig-0003){ref-type="fig"}E and [S3E](#cas14026-sup-0003){ref-type="supplementary-material"}). In tRCC1 and tRCC2 lines, *Trpm1* and *Trpm3* expression levels were significantly increased relative to levels seen in M‐1 cells, suggesting that expression of miR‐211‐5p and miR‐204‐5p as well as *Trpm1* and *Trpm3* is positively correlated with expression of PRCC‐TFE3 fusion proteins in kidney cancer cells.

3.4. Presence of TFE3 fusion proteins increases miR‐204‐5p and miR‐211‐5p expression in human kidney cells {#cas14026-sec-0018}
----------------------------------------------------------------------------------------------------------

To assess whether miR‐204‐5p and miR‐211‐5p could serve as diagnostic markers of pretumorigenic stages of Xp11 tRCC, we first monitored miR‐204‐5p and miR‐211‐5p expression in the HEK293/PRCC‐TFE3 cell line, which is a human embryonic kidney cell line (HEK293) harboring a doxycycline‐dependent *PRCC‐TFE3* fusion gene (Figure [4](#cas14026-fig-0004){ref-type="fig"}). As expected, levels of PRCC‐TFE3 fusion proteins markedly increased in doxycycline‐treated relative to untreated HEK293/PRCC‐TFE3 cells, and those proteins were predominantly nuclear in doxycycline‐treated cells (Figure [4](#cas14026-fig-0004){ref-type="fig"}A,B). Expression levels of both miR‐204‐5p and miR‐211‐5p significantly increased in doxycycline‐treated relative to untreated HEK293/PRCC‐TFE3 cells (Figure [4](#cas14026-fig-0004){ref-type="fig"}C), as did *TRPM1* and *TRPM3* expression (Figure [4](#cas14026-fig-0004){ref-type="fig"}D). These results suggest that TFE3 fusion proteins could upregulate expression of miR‐204‐5p, miR‐211‐5p, and *TRPM* genes in human kidney cells.

![Presence of PRCC‐TFE3 fusion proteins in HEK293 cells increases expression of microRNA (miR)‐204‐5p, miR‐211‐5p, and *TRPM* genes. A, Representative immunoblot (IB) of endogenous TFE3 protein and PRCC‐TFE3 fusion protein in HEK293/PRCC‐TFE3 cells treated with (+) or without (−) doxycycline (DOX). Hsc70 served as a loading control. B, Representative immunoblot showing endogenous TFE3 proteins and PRCC‐TFE3 fusion proteins in cytoplasmic (C) or nuclear (N) fractions of HEK293/PRCC‐TFE3 cells treated with or without DOX. GAPDH and histone H3 served as loading controls for cytoplasmic and nuclear fractions, respectively. C, Relative miR‐204‐5p and miR‐211‐5p expression in HEK293/PRCC‐TFE3 cells treated with or without DOX (n = 4). D, Relative *TRPM3* and *TRPM1* expression in HEK293/PRCC‐TFE3 cells treated with or without DOX (n = 4). Data are means ± SEM. \**P *\<* *.05; \*\**P *\<* *.01. N.D., not detected](CAS-110-1897-g004){#cas14026-fig-0004}

3.5. Expression of miR‐204‐5p and *TRPM3* is upregulated in human Xp11 tRCC cell lines {#cas14026-sec-0019}
--------------------------------------------------------------------------------------

To determine whether miR‐204‐5p and miR‐211‐5p expression increases in tumors of Xp11 tRCC patients, we assessed expression of both miRNAs and of *TRPM* genes in the human UOK120 and UOK124 lines, which were established from tumor tissues of 2 independent Xp11 tRCC patients.[3](#cas14026-bib-0003){ref-type="ref"} The molecular weight of PRCC‐TFE3 fusion proteins reportedly varies due to differences in *PRCC* and *TFE3* gene breakpoints in individual patients.[2](#cas14026-bib-0002){ref-type="ref"} Accordingly, immunoblotting analysis with the TFE3 Ab revealed that UOK120 and UOK124 cells abundantly express PRCC‐TFE3 fusion proteins of \~78 and \~125 kDa, respectively. In addition, expression levels of these fusion proteins were higher than those of endogenous TFE3 proteins in the human renal tubular epithelial cell line HK‐2, and fusion proteins were predominantly nuclear in that line (Figure [5](#cas14026-fig-0005){ref-type="fig"}A,B).

![Expression of microRNA (miR)‐204‐5p and TRPM3 increases in human Xp11 translocation renal cell carcinoma (tRCC) lines. A, Representative immunoblot (IB) of endogenous TFE3 proteins and PRCC‐TFE3 fusion proteins in the human renal tubular epithelial cell line HK‐2 and in the human Xp11 tRCC lines UOK120 and UOK124. Hsc70 served as a loading control. B, Representative immunoblot of endogenous TFE3 protein and PRCC‐TFE3 fusion proteins in cytoplasmic (C) and nuclear (N) fractions of HK‐2, UOK120, and UOK124 cells. GAPDH and histone H3 served as loading controls for cytoplasmic and nuclear fractions, respectively. C,D, Relative miR‐204‐5p and miR‐211‐5p levels in total RNA isolated from HK‐2 and human Xp11 tRCC cells (n = 4) (C) and exosomal RNA isolated from culture supernatants of HK‐2 and human Xp11 tRCC cells (n = 3) (D). E, Relative *TRPM3* and *TRPM1* expression in HK‐2 and human Xp11 tRCC cells (n = 6). Data are means ± SEM. \**P *\<* *.05; \*\**P *\<* *.01. N.D., not detected; N.S., no statistical difference](CAS-110-1897-g005){#cas14026-fig-0005}

We next examined miR‐211‐5p and miR‐204‐5p expression in UOK120, UOK124, and HK‐2 cells (Figure [5](#cas14026-fig-0005){ref-type="fig"}C). Unexpectedly, miR‐211‐5p was not detectable in any of the 3 lines; however, miR‐204‐5p expression levels in UOK120 and UOK124 cells were significantly higher than those in HK‐2 cells. Moreover, miR‐211‐5p was not detected in exosomes from cultured UOK120 and UOK124 cell supernatants, whereas miR‐204‐5p levels in exosomes isolated from supernatants from both lines were significantly higher than those in HK‐2 cells (Figure [4](#cas14026-fig-0004){ref-type="fig"}D). Accordingly, we observed no difference in *TRPM1* expression among UOK120, UOK124, and HK‐2 cells, whereas *TRPM3* expression levels significantly increased in UOK120 and UOK124 relative to HK‐2 cells (Figure [5](#cas14026-fig-0005){ref-type="fig"}E). These results show that expression of both miR‐204‐5p and *TRPM3* is upregulated in human Xp11 tRCC cells and that human Xp11 tRCC cells secrete exosomes containing miR‐204‐5p.

3.6. PRCC‐TFE3 knockdown decreases expression of miR‐204‐5p and *TRPM3* in noncancerous kidney cells but not in human Xp11 tRCC cells {#cas14026-sec-0020}
-------------------------------------------------------------------------------------------------------------------------------------

Finally, to determine whether PRCC‐TFE3 fusion proteins regulate miR‐204‐5p and *TRPM3* expression in human Xp11 tRCC cells, we transfected UOK120 and UOK124 cells with negative control siRNA (siControl) or with 1 of 2 *TFE3*‐specific siRNAs (siTFE3‐1 and siTFE3‐2) (Figure [S4](#cas14026-sup-0004){ref-type="supplementary-material"}). Immunoblotting analysis revealed decreased levels of PRCC‐TFE3 fusion proteins in siTFE3‐1‐ or siTFE3‐2‐transfected Xp11 tRCC cells relative to control cells (Figure [S4A](#cas14026-sup-0004){ref-type="supplementary-material"}). Given that siTFE3‐2 more potently decreased fusion protein levels in both UOK120 and UOK124 cells, we used it in further knockdown analyses.

Unexpectedly, expression levels of miR‐204‐5p in PRCC‐TFE3‐knockdown cells were comparable to those seen in control cells (Figure [S4B](#cas14026-sup-0004){ref-type="supplementary-material"}). In addition, *TRPM3* expression was comparable in PRCC‐TFE3‐knockdown and control cells (Figure [S4C](#cas14026-sup-0004){ref-type="supplementary-material"}). We further examined the effect of PRCC‐TFE3 knockdown on expression of miR‐204‐5p and *TRPM3* in the inducible HEK293/PRCC‐TFE3 cell line (Figure [S5](#cas14026-sup-0005){ref-type="supplementary-material"}). Levels of PRCC‐TFE3 fusion proteins in doxycycline‐treated HEK293/PRCC‐TFE3 cells also markedly decreased following transfection with siTFE3‐2 (Figure [S5A](#cas14026-sup-0005){ref-type="supplementary-material"}). Furthermore, PRCC‐TFE3 knockdown significantly reduced expression levels of miR‐204‐5p and *TRPM3* in doxycycline‐treated HEK293/PRCC‐TFE3 cells (Figure [S5B,C](#cas14026-sup-0005){ref-type="supplementary-material"}). Taken together, these results suggest that expression of both miR‐204‐5p and *TRPM3* in noncancerous kidney cells is upregulated in a TFE3 fusion protein‐dependent manner, whereas TFE3 fusion proteins are no longer required for their expression in Xp11 tRCC cells.

4. DISCUSSION {#cas14026-sec-0021}
=============

Here, we show that miR‐204‐5p levels in urinary exosomes from our established Xp11 tRCC mouse model significantly increase relative to those in control mice. Significantly, these increases occurred at time points prior to overt tRCC development. We also show significantly increased expression of miR‐204‐5p and *TRPM3* not only in cancer cell lines established from tumor tissues of renal *PRCC‐TFE3* Tg mice or human Xp11 tRCC patients, but also in noncancerous human kidney cells overexpressing the *PRCC‐TFE3* fusion gene. Moreover, we found that tRCCs secrete exosomes containing miR‐204‐5p. These findings suggest that the presence of miR‐204‐5p in urinary exosomes could be a useful biomarker for early detection of Xp11 tRCC.

Experimentally, we observed tRCC development in kidney tissues of 30‐ and 40‐week‐old renal *PRCC‐TFE3* Tg mice, but that development was not apparent in 10‐ or 20‐week‐old Tg mice. However, levels of miR‐204‐5p in urinary exosomes were already detectable in 20‐week‐old Tg mice. We also observed no difference in miR‐204‐5p levels in urinary exosomes in Tg mice between 20 and 40 weeks of age. Moreover, PRCC‐TFE3 fusion proteins accumulated in the nuclei of renal tubular epithelial cells in Tg mice. These findings suggest that increased miR‐204‐5p levels in the urinary exosomes occur following expression of constitutively active PRCC‐TFE3 fusion proteins before overt tRCC development and progression. These observations support the idea that miR‐204‐5p in urinary exosomes could serve as an early diagnostic biomarker of Xp11 tRCC progression at pretumorigenic disease stages.

Renal cell carcinomas, including Xp11 tRCC, show few early clinical symptoms. In addition, Xp11 tRCC in humans often recurs and metastasizes, and patients show poor prognosis.[11](#cas14026-bib-0011){ref-type="ref"} However, if a patient\'s tumor is detected early, before metastasis, surgical resection is associated with cure in a high percentage of patients. Typical metastasis of RCCs occurs in lung, bone, liver, and lymph node,[30](#cas14026-bib-0030){ref-type="ref"} suggesting that detecting significant increases of miR‐204‐5p in circulation could be useful to monitor the possibility of metastasis in these patients. Future studies are necessary to investigate whether alterations in exosomal miR‐204‐5p levels are detectable in other body fluids, such as blood, of patients with advanced Xp11 tRCC.

Our study also shows that, in addition to miR‐204‐5p, expression levels of miR‐211‐5p increase in urinary exosomes of renal *PRCC‐TFE3* Tg mice, in primary tRCC cell lines established from tumor tissues of renal *PRCC‐TFE3* Tg mice, and in HEK293 cells overexpressing the *PRCC‐TFE3* fusion gene. However, we did not detect miR‐211‐5p in human Xp11 tRCC lines that show abundant miR‐204‐5p expression. Recent studies have reported downregulated miR‐211‐5p expression in tumor tissues of human RCC patients and in several human RCC lines, and miR‐211‐5p also reportedly functions as a tumor suppressor in human RCC cells.[31](#cas14026-bib-0031){ref-type="ref"}, [32](#cas14026-bib-0032){ref-type="ref"} Collectively, these findings suggest that miR‐211‐5p expression in human Xp11 tRCC cells is silenced, as it is in other RCC cells. However, as we observed a significant increase in miR‐211‐5p levels in both urinary exosomes of 20‐week‐old renal *PRCC‐TFE3* Tg mice and in PRCC‐TFE3‐overexpressing HEK293 cells, miR‐211‐5p silencing might not occur in renal tubular epithelial cells expressing constitutively active TFE3 fusion proteins at pretumorigenic Xp11 tRCC stages. It would be of interest to investigate whether either miR‐204‐5p or miR‐211‐5p contained in liquid biopsy samples predicts Xp11 tRCC occurrence in patients prior to overt tRCC development.

We showed that increased miR‐204‐5p levels in urinary exosomes from renal *PRCC‐TFE3* Tg mice are correlated with tRCC progression. These results implicate miR‐204‐5p target genes in Xp11 tRCC development. We undertook an in silico analysis using the TargetScan database[33](#cas14026-bib-0033){ref-type="ref"} and observed miR‐204‐5p binding sites in the 3′‐UTR or ORF of 615 genes (Table [S3](#cas14026-sup-0008){ref-type="supplementary-material"}). Among the top 100 target genes, several are associated with RCC. For example, 2 potential targets, von Hippel‐Lindau (*VHL*) and chromodomain helicase DNA binding protein 5 (*CHD5*), function as tumor suppressors in RCC.[34](#cas14026-bib-0034){ref-type="ref"}, [35](#cas14026-bib-0035){ref-type="ref"} Among others, high‐mobility group AT‐hook 2 (*HMGA2*) facilitates the epithelial‐mesenchymal transition of RCC cells[36](#cas14026-bib-0036){ref-type="ref"} and Ras‐related protein RAB22A accelerates RCC cell proliferation and invasion.[37](#cas14026-bib-0037){ref-type="ref"} Thus, miR‐204‐5p‐mediated inhibition of tumor suppressors might underlie the development and progression of Xp11 tRCC, although these mechanisms should be addressed in future studies.

Here, we showed that although human Xp11 tRCC cells show increased expression of miR‐204‐5p and *TRPM3*, PRCC‐TFE3 knockdown does not alter their expression. The MiT family proteins, including TFE3, activate transcription of targets through the E‐box consensus motif CANNTG,[9](#cas14026-bib-0009){ref-type="ref"} as do TFE3 fusion proteins.[2](#cas14026-bib-0002){ref-type="ref"}, [9](#cas14026-bib-0009){ref-type="ref"} Numerous transcription factors reportedly bind E‐boxes and some, such as myc and hypoxia‐inducible factor, are activated in human RCC cells.[34](#cas14026-bib-0034){ref-type="ref"}, [38](#cas14026-bib-0038){ref-type="ref"} These factors might also contribute to expression of both miR‐204‐5p and *TRPM3* in Xp11 tRCC cells.

Loss‐of‐function germline mutations in *folliculin* (*FLCN*) cause development of RCC, fibrofolliculomas, and lung cysts in Birt‐Hogg‐Dube (BHD) syndrome.[39](#cas14026-bib-0039){ref-type="ref"}, [40](#cas14026-bib-0040){ref-type="ref"} FLCN reportedly inhibits TFE3 activation, and TFE3 protein is nuclear in tumor tissues of BHD patients.[41](#cas14026-bib-0041){ref-type="ref"} In addition, recent studies show that increased transcriptional activity of MiTF, a MiT family member, caused by a germline missense mutation in *MiTF*, increases the risk of developing RCC and melanoma.[42](#cas14026-bib-0042){ref-type="ref"} Furthermore, a different study reported that amplification of *TFEB*, another MiT family member, occurs in some RCC patients and that overexpressed TFEB proteins localize in tumor cell nuclei.[43](#cas14026-bib-0043){ref-type="ref"} Therefore, expression of miR‐204‐5p and *TRPM3* could increase in MiT family protein‐activated renal tumors.

In summary, we found that miR‐204‐5p levels in urinary exosomes are significantly increased in both pretumorigenic and tumor developing stages in renal *PRCC‐TFE3* Tg mice. We also report upregulated miR‐204‐5p expression in both human nontumor kidney cells harboring PRCC‐TFE3 fusion proteins and in human Xp11 tRCC cells, and that human Xp11 tRCC cells secrete exosomes containing miR‐204‐5p. We propose that estimation of miR‐204‐5p levels in urinary exosomes could be a useful biomarker to diagnose Xp11 tRCC at both pretumorigenic and advanced stages.
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